Pharmaron Beijing Co (SZSE:300759) Short-Term Debt & Capital Lease Obligation : ¥864 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Pharmaron Beijing Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥864 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Pharmaron Beijing Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥7,388 Mil.

Pharmaron Beijing Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Pharmaron Beijing Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Short-Term Debt & Capital Lease Obligation Chart

Pharmaron Beijing Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

364.80

470.07

577.59

901.75

912.73

Pharmaron Beijing Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															926.36	726.78	812.73	912.73	864.47

Pharmaron Beijing Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Pharmaron Beijing Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co (SZSE:300759) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

03759:Hong Kong 17Q1:Germany

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.

Executives

Lou Xiao Qiang	Directors, executives
Zheng Bei	Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines